MGAT2 deficiency ameliorates high-fat diet-induced obesity and insulin resistance by inhibiting intestinal fat absorption in mice

Takuma Tsuchida(Mitsubishi Tanabe Pharma Corporation), Sayaka Fukuda(Mitsubishi Tanabe Pharma Corporation), Hisanori Aoyama(Mitsubishi Tanabe Pharma Corporation), Nobuhiko Taniuchi(Mitsubishi Tanabe Pharma Corporation), Tomomi Ishihara(Mitsubishi Tanabe Pharma Corporation), Noriko Ohashi(Mitsubishi Tanabe Pharma Corporation), Hiroko Sato(Mitsubishi Tanabe Pharma Corporation), Koji Wakimoto(Mitsubishi Tanabe Pharma Corporation), Masaharu Shiotani(Mitsubishi Tanabe Pharma Corporation), Akira Oku(Mitsubishi Tanabe Pharma Corporation)
Lipids in Health and Disease
January 1, 2012
Cited by 42Open Access
Full Text

Abstract

BACKGROUND: Resynthesis of triglycerides in enterocytes of the small intestine plays a critical role in the absorption of dietary fat. Acyl-CoA:monoacylglycerol acyltransferase-2 (MGAT2) is highly expressed in the small intestine and catalyzes the synthesis of diacylglycerol from monoacylglycerol and acyl-CoA. To determine the physiological importance of MGAT2 in metabolic disorders and lipid metabolism in the small intestine, we constructed and analyzed Mgat2-deficient mice. RESULTS: In oral fat tolerance test (OFTT), Mgat2-deficient mice absorbed less fat into the circulation. When maintained on a high-fat diet (HFD), Mgat2-deficient mice were protected from HFD-induced obesity and insulin resistance. Heterozygote (Mgat2+/-) mice had an intermediate phenotype between Mgat2+/+ and Mgat2-/- and were partially protected from metabolic disorders. Despite of a decrease in fat absorption in the Mgat2-deficient mice, lipid levels in the feces and small intestine were comparable among the genotypes. Oxygen consumption was increased in the Mgat2-deficient mice when maintained on an HFD. A prominent upregulation of the genes involved in fatty acid oxidation was observed in the duodenum but not in the liver of the Mgat2-deficient mice. CONCLUSION: These results suggest that MGAT2 has a pivotal role in lipid metabolism in the small intestine, and the inhibition of MGAT2 activity may be a promising strategy for the treatment of obesity-related metabolic disorders.


Related Papers

No related papers found

Powered by citation graph analysis